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Figure S1. Fluorination plot for cytisine at TyrC2 in the A2B3 stoichiometry. (A) Fluorination plot showing Fn-Phe series in 
blue (R2=0.77). The x-axis is the calculated binding energy between a Sodium ion and each side chain in the gas phase.1 The y-
axis is the log fold shift in EC50. 
 
Table S1. Cytisine EC50 values for non-canonical amino acids at TyrC2 in A2B3. 
Residue EC50 (μM) nH   Fold shift to WT Fold shift to Phe N | Imax | 
Tyr 0.0056 ± 0.0001 1.4 ± 0.04 1.0 
 
13 0.11-1.9 
Phe 0.012 ± 0.0003 1.4 ± 0.05 2.1 1.0 18 0.054-0.84 
4-F1-Phe 0.014 ± 0.0005 1.4 ± 0.07 2.5 1.2 16 0.022-0.54 
3,5-F2-Phe 0.34 ± 0.02 1.3 ± 0.1 60 28 8 0.009-0.10 
3,4,5-F3-Phe 0.20 ± 0.009 1.3 ± 0.07 36 17 13 0.034-0.30 
 
 
Table S2. EC50 values for cytisine derivatives at WT A2B3. 
Ligand EC50 (nM) nH Fold 
shift 
N Efficacy |Imax| (μA) 
1 Cytisine 5.6 ± 0.1 1.4 ± 0.04 1.0 13 0.05 0.1 – 2.1  
2 F 7.1 ± 0.1 1.4 ± 0.03 1.3 14 0.10 0.4 – 16 
3 Me 13 ± 0.2 1.4 ± 0.03 2.3 12 0.16 0.5 – 8.7 
4 OMe 76 ± 2 1.4 ± 0.04 14 13 0.08 0.3 – 1.0 
5 CF3 100 ± 3 1.3 ± 0.04 18 14 0.06 0.9 – 5.1 
10 NHCH3 260 ± 4 1.1 ± 0.02 44 12 0.19 1.1 – 4.5 
 
1 Duffy, N. H. Studies of the Serotonin Type 3A Receptor and the Chemical Preparation of TRNA. phd, California 
Institute of Technology, 2014. https://doi.org/Duffy, Noah Hanville  (2014)  Studies of the Serotonin Type 3A 
Receptor and the Chemical Preparation of tRNA.  Dissertation (Ph.D.), California Institute of Technology.  
doi:10.7907/X1YA-DM13.   http://resolver.caltech.edu/CaltechTHESIS:05062014-151417635 
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11 Br/ NHCH3 230 ± 6 1.2 ± 0.03 37 13 0.29 0.35 - 2.2 
6 Et 24 ± 0.5 1.2 ± 0.03 4.3 16 0.16 0.34 -3.9 
7 Br/ Et 1.2 ± 0.02 2.3 ± 0.08 0.21 14 0.33 0.86 – 8.6 
8 NH2 30 ± 0.8 1.2 ± 0.03 5.4 16 0.18 0.40 - 3.7 
9 Br/ NH2 1.3 ± 0.02 1.9 ± 0.05 0.23 23 0.29 0.83 – 5.4 
 
 
Figure S2. Dose-response curves of cytisine derivatives to the α7 nAChR. The cytisine structure indicated the position of the 
substituent at C(10). The EC50 of NHCH3-cytisine was too far right-shifted to record a full dose-response relation. 
 
Table S3. EC50 values for cytisine derivatives at WT α7. ND: not determined. 
Ligand EC50 (μM) nH   Fold shift N Efficacy |Imax| 
1 Cytisine 40 ± 1 1.5 ± 0.07 1.0 11 ND 0.86-14 
2 F 110 ± 2 3.1 ± 0.2 2.8 6 ND 0.050-5.6 
5 CF3 110 ± 4 2.4 ± 0.2 2.6 7 0.16 0.22-4.1 
4 OMe 330 ± 8 2.8 ± 0.2 8.1 8 0.37 0.37-18 
3 Me 390 ± 14 2.7 ± 0.2 9.7 7 0.35 0.42-11 
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Figure S3. Investigation of steric effects on C(10)-substitution in A3B2. (A) Dose-response curves for C(10)-derivatives with 
increased steric bulk. Cytisine derivatives used in this series; 3 (Me), 6 (Et), 12 (C(CH3)CH2), 13 (CH(CH3)2), 14 (C(CH3)3). 
 
Table S4. EC50 values for cytisine derivatives, sterics series, at WT A3B2. Volume of ligand was calculated after 
equilibrium geometry optimization using HF-6-31** in vacuum. 
Ligand EC50 (nM) nH Fold shift N Efficacy Imax Volume (Å3) 
1 cytisine 1.3 ± 0.02 1.9 ± 0.05 1.0 12 0.73 0.22-27 198 
3 Me 2.5 ± 0.2 1.8 ± 0.04 1.9 13 0.67 0.37-47 216 
6 Et 3.3 ± 0.06 1.7 ± 0.04 2.5 16 0.51 1.1-36 234 
12 C(CH3)CH2 56 ± 2 1.5 ± 0.06 44 12 0.14 0.28-5.8 249 
13 CH(CH3)2 53 ± 2 1.4 ± 0.03 42 17 0.06 0.055-4.0 252 
14 C(CH3)3 45 ± 0.5 2.0 ± 0.04 35 10 0.67 1.0-24 270 
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Figure S4. Conformational analysis of cytisine derivatives with NHCH3 and Et-substituents at C(10). Lowest energy conformers 
of 6 (Et) and 7 (Br/Et) have the C(10)-substituent perpendicular to the pyridone ring, while 10 (NHCH3) and 11 (Br/NHCH3) 
have the substituent in the plane of the ring. 
 
 
 
Figure S5. Scatterplot, EC50 fold shifts of C(10) derivatives vs logD7.5. (A) Values for A3B2 stoichiometry and (B) values for 
A2B3 stoichiometry. 
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Table S5. Calculated electrostatic potentials of carbonyl and amine in cytisine derivatives, as well as the total volume of 
the ligand. 
Ligand 
 
Carbonyl (kcal/mol) Amine (kcal/mol) Volume (Å3) 
5  CF3 
 
8.4 171 230 
2  F 
 
4.6 170 203 
1 cytisine 
 
2.9 168 198 
3  Me 
 
0.94 166 216 
6  Et 
 
0.44 166 234 
12 C(CH3)CH2  0.35 166 249 
13 CH(CH3)2 
 
0.11 166 252 
4  OMe 
 
0.03 166 225 
14 C(CH3)3 
 
0.03 165 270 
7 Br/ Et 
 
-2.1 168 253 
8 NH2 
 
-3.6 165 208 
9 Br/ NH2 
 
-5.9 167 226 
10 NHCH3 
 
-5.9 164 228 
11 Br/NHCH3 
 
-8.1 166 246 
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Table S6. EC50 and nH values for nonsense-suppression experiments at W154 in A3B2. 
Ligand Residue EC50 (nM) nH   Fold shift N |Imax| 
1 Cytisine Trp 1.2 ± 0.024 2.2 ± 0.08 
 
21 0.082 – 4.0 
  F4-Trp 14 ± 0.81 1.1 ± 0.07 12 10 0.075 – 0.15 
10 NHCH3 Trp 41 ± 55 1.4 ± 0.2  12 1.5 – 16 
   1300 ± 120 1.7 ± 0.6    
  F4-Trp 1100 ± 51 1.1 ± 0.06 27 14 0.080 – 0.70 
5 CF3 Trp 19 ± 0.72 1.4 ± 0.07  10 0.055 – 6.05 
  F4-Trp 780 ± 82 0.91 ± 0.08 41 10 0.087 – 0.54 
4 OMe Trp 15 ± 0.39 1.9 ± 0.08  17 0.18 – 8.8 
  F4-Trp 760 ± 61 0.99 ± 0.07 51 10 0.021 – 0.23 
2 F Trp 1.6 ± 0.039 2.1 ± 0.1  11 0.22 – 7.3 
  F4-Trp 150 ± 7.9 1.1 ± 0.05 96 11 0.069 – 0.64 
3 Me Trp 3.3 ± 0.086 1.8 ± 0.07  17 0.056 – 6.6 
  F4-Trp 140 ± 8.1 1.1 ± 0.07 46 10 0.087 – 0.56 
6 Et Trp 2.7 ± 0.078 1.7 ± 0.08  12 0.051 – 15 
  F4-Trp 460 ± 12 1.0 ± 0.03 170 11 0.063 – 0.58 
8 NH2 Trp 8.5 ± 0.46 1.5 ± 0.1  13 0.16 – 15 
  F4-Trp 550 ± 72 1.0 ± 0.1 65 9 0.033 – 0.78 
14 C(CH3)3 Trp 44 ± 1.1 1.7 ± 0.06  15 1.9 – 29 
  F4-Trp 270 ± 120 1.3 ± 0.07 61 12 0.072 – 0.75 
9 Br/NH2 Trp 0.65 ± 0.042 1.9 ± 0.2  11 0.78 – 14 
  F4-Trp 21 ± 0.98 1.0 ± 0.05 33 11 0.063 – 0.97 
7 Br/Et Trp 0.41 ± 0.023 2.4 ± 0.3  9 1.3 – 17 
  F4-Trp 14 ± 0.55 1.1 ± 0.05 34 12 0.077 – 1.9 
11 Br/NHCH3 Trp 31 ± 24 1.4 ± 0.1  12 0.89 – 25 
   2600 ± 140 2.2 ± 1    
  F4-Trp 1900 ± 94 1.2 ± 0.07 61 13 0.074 – 0.22 
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Table S7. EC50 and nH values for nonsense-suppression experiments at T155 in A3B2. 
 Ligand Residue EC50 (nM) nH   Fold shift N |Imax| 
1 Cytisine Thr 1.7 ± 0.030 1.7 ± 0.05 
 
12 0.26 - 12 
  Tah 46 ± 1.1 1.2 ± 0.03 27 12 0.30 - 13 
10 NHCH3 Thr 40 ± 78 1.7 ± 0.44  14 0.26 – 17 
   770 ± 290 0.84 ± 0.15    
  Tah 1000 ± 33 1.4 ± 0.06 25 11 0.28 - 14 
5 CF3 Thr 23 ± 0.75 1.3 ± 0.05  10 0.15 – 16 
  Tah 1400 ± 39 1.4 ± 0.04 61 12 0.059 – 8.3 
4 OMe Thr 20 ± 0.35 1.5 ± 0.04  10 0.59 – 9.6 
  Tah 430 ± 15 1.3 ± 0.05 22 10 0.015 – 9.3 
2 F Thr 1.8 ± 0.029 1.5 ± 0.03  12 0.72 – 7.0 
  Tah 60 ± 1.7 1.2 ± 0.03 33 12 0.28 - 13 
3 Me Thr 3.4 ± 0.088 1.5 ± 0.06  13 0.098 – 8.2 
  Tah 100 ± 3.2 1.3 ± 0.05 31 14 0.042 - 14 
6 Et Thr 3.1 ± 0.10 1.4 ± 0.06  12 0.086 – 7.3 
  Tah 170 ± 4.4 1.2 ± 0.03 56 12 0.46 - 11 
8 NH2 Thr 13 ± 0.37 1.3 ± 0.04  13 0.15 – 7.6 
  Tah 220 ± 4.0 1.2 ± 0.02 17 12 2.4 - 15 
14 C(CH3)3 Thr 43 ± 0.98 1.9 ± 0.07  21 0.30 – 15 
  Tah 1100 ± 14 1.4 ± 0.02 26 11 0.16 – 8.7 
9 Br/NH2 Thr 0.40 ± 0.0089 2.2 ± 0.10  13 0.031 – 6.0 
  Tah 3.7 ± 0.084 1.4 ± 0.04 9.3 13 0.45 – 17 
7 Br/Et Thr 0.50 ± 0.016 2.0 ± 0.12  12 0.30 – 7.7 
  Tah 5.6 ± 0.13 1.3 ± 0.03 11 11 1.6 – 20 
11 Br/NHCH3 Thr 38 ± 47 1.3 ± 0.13  20 0.13 – 34 
   3400 ± 150 1.4 ± 0.43    
  Tah 97 ± 31 1.3 ± 0.05 25 10 0.97 - 12 
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Table S8. EC50 and nH values for nonsense-suppression experiments at L119 in A3B2. 
 Ligand Residue EC50 (nM) nH   Fold shift N |Imax| 
1 Cytisine Leu 1.2 ± 0.023 1.9 ± 0.06 
 
13 0.069 – 2.8 
  Lah 38 ± 0.92 1.1 ± 0.03 32 15 0.67 - 23 
10 NHCH3 Leu 41 ± 91 1.5 ± 0.3  11 0.064 – 1.1 
   1300 ± 150 1.1 ± 0.4    
  Lah 1300 ± 20 1.5 ± 0.03 32 13 0.13 – 5.5 
5 CF3 Leu 17 ± 0.66 1.2 ± 0.06  10 0.012 – 1.3 
  Lah 250 ± 4.6 1.1 ± 0.02 15 12 0.030 – 7.6 
4 OMe Leu 18 ± 0.34 1.6 ± 0.05  11 0.057 – 1.0 
  Lah 530 ± 13 1.2 ± 0.03 30 12 0.10 – 7.4 
2 F Leu 2.0 ± 0.029 2.0 ± 0.05  14 0.057 – 0.90 
  Lah 36 ± 0.55 1.2 ± 0.02 18 14 0.53 – 7.9 
3 Me Leu 2.8 ± 0.074 1.8 ± 0.07  11 0.11 – 1.0 
  Lah 130 ± 2.6 1.1 ± 0.02 46 11 0.050 – 2.7 
6 Et Leu 4.5 ± 0.24 1.2 ± 0.07  11 0.075 – 1.4 
  Lah 79 ± 3.1 1.2 ± 0.05 18 12 0.31 – 4.9 
8 NH2 Leu 9.5 ± 0.19 1.4 ± 0.03  15 0.48 – 16 
  Lah 230 ± 4.1 1.2 ± 0.02 25 14 0.077 – 49 
14 C(CH3)3 Leu 49 ± 0.86 1.8 ± 0.05  16 0.14 – 11 
  Lah 950 ± 17 1.4 ± 0.03 19 16 0.79 - 33 
9 Br/NH2 Leu 0.41 ± 0.0068 2.2 ± 0.07  12 0.32 – 5.2 
  Lah 2.4 ± 0.043 1.6 ± 0.04 5.9 11 1.1 – 28 
7 Br/Et Leu 0.40 ± 0.020 1.4 ± 0.1  13 0.055 – 0.47 
  Lah 1.0 ± 0.047 1.6 ± 0.1 2.5 12 0.20 – 7.1 
11 Br/NHCH3 Leu 37 ± 48 1.4 ± 0.2  13 0.32 – 11 
   2900 ± 130 1.6 ± 0.7    
  Lah 410 ± 11 1.2 ± 0.03 11 14 10 - 46 
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Table S9. EC50 and nH values for nonsense-suppression experiments at Y202 in A3B2. 
 Ligand Residue EC50 (nM) nH   Fold shift N |Imax| 
1 Cytisine Phe 6.6 ± 0.14 1.4 ± 0.04 
 
13 0.064 – 22 
  F3-Phe 160 ± 6.3 1.1 ± 0.05 24 13 0.44 – 8.0 
10 NHCH3 Phe 53 ± 71 1.3 ± 0.3  18 0.10 – 12 
   5700 ± 69 1.4 ± 0.3    
  F3-Phe 5300 ± 300 1.0 ± 0.06 100 15 0.025 – 2.9 
5 CF3 Phe 6.9 ± 0.78 0.78 ± 0.06  12 0.64 – 8.6 
  F3-Phe 460 ± 38 1.17 ± 0.1 67 12 0.14 – 0.83 
4 OMe Phe 28 ± 4.4 0.71 ± 0.1  14 0.25 – 6.3 
  F3-Phe 1500 ± 120 0.76 ± 0.05 54 16 0.17 – 0.83 
2 F Phe 10 ± 0.69 0.78 ± 0.04  15 0.31 – 8.9 
  F3-Phe 190 ± 10 0.88 ± 0.04 19 16 0.21 – 1.1 
3 Me Phe 14 ± 1.1 0.76 ± 0.05  14 0.16 – 7.5 
  F3-Phe 140 ± 8.4 1.0 ± 0.06 10 13 0.059 – 0.50 
6 Et Phe 2.3 ± 0.077 1.9 ± 0.1  14 0.040 – 3.3 
  F3-Phe 160 ± 6.9 1.3 ± 0.07 70 10 0.15 – 1.3 
8 NH2 Phe 36 ± 1.1 1.4 ± 0.05  14 0.50 – 8.5 
  F3-Phe 2200 ± 67 1.2 ± 0.04 61 11 0.088 – 5.7 
14 C(CH3)3 Phe 160 ± 12 0.96 ± 0.07  12 0.064 – 0.67 
  F3-Phe 6000 ± 590 1.0 ± 0.09 38 9 0.017 – 0.32 
9 Br/NH2 Phe 0.68 ± 0.018 2.5 ± 0.2  11 0.043 – 7.7 
  F3-Phe 30 ± 0.84 1.1 ± 0.03 44 6 0.30 – 2.4 
7 Br/Et Phe 0.41 ± 0.020 2.6 ± 0.3  15 0.053 – 7.6 
  F3-Phe 13 ± 1.3 0.73 ± 0.06 32 9 0.10 – 10 
11 Br/NHCH3 Phe 3.0 ± 42 1.6 ± 0.2  17 0.081 – 13 
   260 ± 110 1.2 ± 0.4    
  F3-Phe 280 ± 52 1.0 ± 0.1 93 16 0.49 – 5.4 
   8900 ± 100 2.7 ± 2    
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Table S10. EC50 and nH values for nonsense-suppression experiments at W154 in A2B3. 
 Ligand Residue EC50 (nM) nH   Fold shift N |Imax| 
1 Cytisine Trp 4.0 ± 0.21 1.3 ± 0.09 
 
15 0.053 – 1.1 
  F4-Trp 97 ± 3.5 0.97 ± 0.03 23 9 0.057 – 0.17 
10 NHCH3 Trp 150 ± 5.9 1.2 ± 0.05  13 0.16 – 4.3 
  F4-Trp 1800 ± 58 1.2 ± 0.04 12 14 0.088 – 1.1 
5 CF3 Trp 70 ± 2.2 1.2 ± 0.05  14 0.18 – 4.5 
  F4-Trp 1100 ± 38 1.3 ± 0.05 16 10 0.14 – 0.75 
4 OMe Trp 43 ± 2.2 1.5 ± 0.1  14 0.10 – 2.6 
  F4-Trp 710 ± 25 1.2 ± 0.05 17 10 0.054 – 0.41 
2 F Trp 7.7 ± 0.27 1.6 ± 0.08  14 0.13 – 2.1 
  F4-Trp 200 ± 7.9 1.1 ± 0.05 26 13 0.051 – 0.22 
3 Me Trp 6.3 ± 0.22 1.6 ± 0.08  12 0.24 – 2.1 
  F4-Trp 150 ± 6.8 1.2 ± 0.06 24 11 0.023 – 0.26 
6 Et Trp 16 ± 0.55 1.6 ± 0.08  14 0.072 – 0.79 
  F4-Trp 380 ± 32 1.1 ± 0.1 24 11 0.011 – 0.84 
8 NH2 Trp 33 ± 1.2 1.3 ± 0.06  16 0.28 - 6.2 
  F4-Trp 590 ± 20 1.0 ± 0.03 18 9 0.023 – 0.85 
14 C(CH3)3 Trp 140 ± 5.9 1.4 ± 0.07  11 0.088 – 2.3 
  F4-Trp 6200 ± 550 1.2 ± 0.1 44 17 0.015 – 1.2 
9 Br/NH2 Trp 1.9 ± 0.11 1.8 ± 0.2  12 0.15 - 11 
  F4-Trp 19 ± 0.80 1.1 ± 0.05 10 12 0.14 – 1.2 
7 Br/Et Trp 0.86 ± 0.024 2.9 ± 0.2  10 0.33 – 1.4 
  F4-Trp 16 ± 0.74 1.1 ± 0.05 19 6 0.060 – 0.25 
11 Br/NHCH3 Trp 140 ± 3.9 1.2 ± 0.04  11 0.21 – 3.2 
  F4-Trp 3000 ± 190 1.2 ± 0.08 21 18 0.017 – 0.19 
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Table S11. EC50 and nH values for nonsense-suppression experiments at T155 in A2B3. 
 Ligand Residue EC50 (nM) nH   Fold shift N |Imax| 
1 Cytisine Thr 7.2 ± 0.18 1.4 ± 0.04 
 
12 0.19 – 0.56 
  Tah 130 ± 2.5 1.2 ± 0.02 18 10 0.024 – 0.43 
10 NHCH3 Thr 180 ± 3.3 1.33 ± 0.03  13 0.048 – 0.49 
  Tah 2800 ± 52 1.4 ± 0.03 16 12 0.23 – 2.3 
5 CF3 Thr 110 ± 1.6 1.3 ± 0.02  11 0.12 – 0.48 
  Tah 3700 ± 47 1.4 ± 0.02 34 11 0.23 – 1.9 
4 OMe Thr 85 ± 1.8 1.3 ± 0.03  13 0.050 – 0.61 
  Tah 1400 ± 23 1.3 ± 0.03 16 10 0.20 – 0.7.8 
2 F Thr 5.5 ± 0.15 1.3 ± 0.04  9 0.020 – 0.43 
  Tah 170 ± 2.5 1.2 ± 0.02 31 11 0.023 – 1.8 
3 Me Thr 11 ± 0.24 1.4 ± 0.04  7 0.043 – 0.68 
  Tah 330 ± 4.1 1.3 ± 0.02 30 19 0.38 – 2.5 
6 Et Thr 15 ± 0.20 1.5 ± 0.03  15 0.031 – 0.59 
  Tah 680 ± 12 1.3 ± 0.03 45 14 0.11 – 0.94 
8 NH2 Thr 42 ± 0.55 1.2 ± 0.02  12 0.056 – 0.87 
  Tah 850 ± 11 1.2 ± 0.02 20 13 0.053 – 0.47 
14 C(CH3)3 Thr 230 ± 5.4 1.3 ± 0.03  14 0.093 – 0.42 
  Tah 2000 ± 55 1.2 ± 0.03 8.7 15 0.052 – 1.6 
9 Br/NH2 Thr 1.4 ± 0.032 1.8 ± 0.07  14 0.099 – 1.8 
  Tah 16 ± 0.17 1.3 ± 0.02 11 15 0.12 – 1.2 
7 Br/Et Thr 0.89 ± 0.019 2.4 ± 0.1  14 0.20 – 1.6 
  Tah 18 ± 0.37 1.3 ± 0.03 20 15 0.23 – 3.3 
11 Br/NHCH3 Thr 190 ± 3.0 1.2 ± 0.02  13 0.22 – 0.94 
  Tah 2300 ± 37 1.3 ± 0.02 12 15 0.20 – 2.7 
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Table S12. EC50 and nH values for nonsense-suppression experiments at L119 in A2B3. 
 Ligand Residue EC50 (nM) nH   Fold shift N |Imax| 
1 Cytisine Leu 4.9 ± 0.096 1.3 ± 0.03 
 
11 0.078 – 1.3 
  Lah 190 ± 5.1 1.0 ± 0.02 39 12 0.081 – 0.11 
10 NHCH3 Leu 160 ± 6.7 1.0 ± 0.04  7 0.21 – 1.9 
  Lah 3800 ± 76 1.4 ± 0.04 24 11 0.079 – 1.0 
5 CF3 Leu 57 ± 1.3 1.3 ± 0.03  14 0.16 – 3.0 
  Lah 990 ± 20 1.4 ± 0.03 17 12 0.59 – 3.7 
4 OMe Leu 65 ± 1.9 1.2 ± 0.04  10 0.043 – 0.31 
  Lah 2100 ± 30 1.2 ± 0.02 32 13 0.036 – 3.1 
2 F Leu 5.2 ± 0.13 1.5 ± 0.05  11 0.031 – 0.47 
  Lah 170 ± 3.4 1.3 ± 0.03 33 10 0.064 – 0.63 
3 Me Leu 8.7 ± 0.29 1.3 ± 0.05  11 0.11 – 2.0 
  Lah 460 ± 8.3 1.3 ± 0.03 53 11 0.43 – 3.5 
6 Et Leu 18 ± 0.40 1.4 ± 0.04  11 0.097 – 1.1 
  Lah 630 ± 13 1.3 ± 0.03 35 9 0.43 – 1.6 
8 NH2 Leu 43 ± 0.85 1.1 ± 0.02  15 0.3 – 2.4 
  Lah 2200 ± 39 1.2 ± 0.02 51 14 0.044 – 8.2 
14 C(CH3)3 Leu 160 ± 3.9 1.3 ± 0.04  12 0.030 – 0.29 
  Lah 5300 ± 91 1.3 ± 0.03 33 15 0.11 – 0.95 
9 Br/NH2 Leu 1.5 ± 0.024 1.9 ± 0.05  14 0.59 – 3.1 
  Lah 31 ± 0.97 1.2 ± 0.04 21 15 0.24 – 20 
7 Br/Et Leu 0.87 ± 0.018 2.0 ± 0.07  16 0.17 – 2.2 
  Lah 8.1 ± 0.22 1.4 ± 0.05 9.3 11 0.96 – 4.6 
11 Br/NHCH3 Leu 160 ± 4.6 1.3 ± 0.04  12 0.080 – 0.81 
  Lah 3000 ± 41 1.2 ± 0.02 19 15 0.12 – 2.7 
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Table S13. EC50 and nH values for nonsense-suppression experiments at Y202 in A2B3. 
 Ligand Residue EC50 (nM) nH   Fold shift N |Imax| 
1 Cytisine Phe 12 ± 0.35 1.4 ± 0.05 
 
18 0.076 – 0.84 
  F3-Phe 200 ± 9.2 1.3 ± 0.07 17 13 0.034 – 0.30 
10 NHCH3 Phe 110 ± 5.7 1.3 ± 0.08  11 0.064 – 0.31 
  F3-Phe 8000 ± 610 1.1 ± 0.08 73 12 0.022 – 0193 
5 CF3 Phe 6.2 ± 0.17 1.5 ± 0.05  16 0.045 – 0.24 
  F3-Phe 720 ± 53 1.2 ± 0.1 116 14 0.008 – 0.040 
4 OMe Phe 42 ± 3.2 1.4 ± 0.1  10 0.017 – 0.086 
  F3-Phe 1400 ± 100 1.4 ± 0.1 33 11 0.010 – 0.19 
2 F Phe 7.9 ± 0.53 1.2 ± 0.09  12 0.036 – 0.16 
  F3-Phe 200 ± 12 1.4 ± 0.1 25 12 0.015 – 0.022 
3 Me Phe 8.6 ± 0.30 1.2 ± 0.05  12 0.036 – 0.30 
  F3-Phe 250 ± 28 1.0 ± 0.1 29 11 0.007 – 0.032 
6 Et Phe 7.9 ± 1.4 1.0 ± 0.1  9 0.017 – 0.072 
  F3-Phe 580 ± 51 1.1 ± 0.1 73 9 0.006 – 0.17 
8 NH2 Phe 85 ± 3.4 1.4 ± 0.07  5 0.054 – 0.136 
  F3-Phe 4000 ± 230 1.3 ± 0.1 47 10 0.010 – 0.096 
14 C(CH3)3 Phe 300 ± 19 1.5 ± 0.1  11 0.014 – 0.13 
  F3-Phe 5000 ± 880 1.4 ± 0.3 17 6 0.005 – 0.017 
9 Br/NH2 Phe 2.1 ± 0.10 1.6 ± 0.1  10 0.064 – 1.6 
  F3-Phe 96 ± 6.2 1.0 ± 0.07 46 6 0.16 – 0.89 
7 Br/Et Phe 1.3 ± 0.042 2.1 ± 0.1  13 0.082 – 0.34 
  F3-Phe 26 ± 1.5 1.1 ± 0.07 20 13 0.025 – 0.27 
11 Br/NHCH3 Phe 10 ± 0.46 1.4 ± 0.08  10 0.21 -0.98 
  F3-Phe 560 ± 27 1.3 ± 0.07 56 11 0.023 – 0.16 
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2. Synthetic methods 
2.1 General synthetic chemistry experimental protocols.  
All reagents were purchased from commercial suppliers and used without further 
purification unless otherwise stated. Anhydrous solvents were obtained by distillation using 
standard procedures or by using the Anhydrous Engineering Ltd. double alumina and alumina-
copper catalyzed drying columns. Reactions requiring anhydrous conditions were run under an 
atmosphere of dry nitrogen; glassware and needles were flamed-dried prior to use or placed in 
the oven (150 °C) for at least 2 h and allowed to cool in a desiccator. Thin layer chromatography 
was performed using aluminum-backed 60 F254 silica plates. Visualization was achieved by UV 
fluorescence or a basic KMnO4 solution and heat. Flash column chromatography was performed 
on silica gel (Aldrich 40-63 µm, 230-400 mesh). 
Infrared spectra were recorded using a Perkin Elmer Spectrum One FT-IR Spectrometer as 
solids or neat films in the range of 600-4000 cm-1. NMR spectra were recorded using either a 
Varian 400 MHz or 500 MHz spectrometer. Chemical shifts are quoted in parts per million, 
coupling constants are given in Hz to the nearest 0.5 Hz. 1H and 13C NMR spectra are referenced 
to the appropriate residual peak. DEPT135, COSY, HSQC and HMBC were used in assigning 
NMR spectra. Melting points were determined using Reichert melting point apparatus. Mass 
spectra were determined by the University of Bristol mass spectroscopy service by electrospray 
ionization (ESI+) using a Bruker Daltonics micrOTOF II spectrometer. 
2.2 Structural assignment and numbering system.  
Structural assignments follow from earlier work2 to develop access to C(10) cytisine 
derivatives and only compounds not previously described are reported here.  
The numbering system described below has been used in the Supplemental Information for NMR 
assignment and discussion of C(10)-monosubstituted and C(9),C(10)-disubstituted cytisine 
derivatives. For simplicity, the cytisine derivatives have been named using the scaffold as shown 
here.   
 
 
2. Campello, H. R.; Del Villar, S. G.; Honraedt, A.; Viñas, T. M.; Oliveira, A. S. F.; Ranaghan, K. E.; Shoemark, 
D. K.; Bermudez, I.; Gotti, C.; Sessions, R. B.; Mulholland, A. J.; Wonnacott, S.; Gallagher, T. Chem, 2018, 4, 
1710-1725. 
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Figure S6. The numbering system for cytisine used here. 3  
 
 
 
 
2.3 Summary and General procedures. 
C(10)-functionalization of N-Boc cytisine (prepared from enantiomerically pure (-)-
cytisine) via iridium-catalysed C‒H activation/borylation has been described previously.1  This 
chemistry was used previously to prepare 10-bromocytisine and C(10) ligands 3, 4, 6, 12, 13 
and 14. In this paper, the C-H activation of N-Boc cytisine has been applied to generate new 
C(10) and C(9)/C(10) ligands using either N-Boc 10-bromocytisine1 or N-Boc 10-iodocytisine 
(described here) as key intermediates. Synthetic details (summarized in schemes 1 and 2), 
including key intermediates and compound characterization data, for novel C(10) ligands 2, 5, 
8 and 10 and the 9-bromo-10-substituted variants 7, 9 and 11 are provided here.    
 
Scheme S1. Transformations to provide ligands 5 and 7. 
 
 
3. Rouden, J.; Lasne, M. C.; Blanchet, J.; Baudoux, J. Chem. Rev. 2014, 114, 712-778. 
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Scheme S2. Transformations from N-Boc 10-bromocytisine to provide derivatives 2, 8, 9, 10 and 11. 
 
(i) General procedure A: C(9) Bromination of C(10)-substituted cytisine derivatives. 
To a solution of the corresponding N-Boc C(10)-substituted cytisine derivative 
(specifically N-Boc precursors of 6, 8 and 10; 1 equiv.) in THF (0.05 M) was added N-
bromosuccinimide (1 equiv.) and the reaction mixture was stirred at room temperature for 18 h. 
Water (10 volumes) was added, and the aqueous phase was extracted with EtOAc (3 x 10 
volumes). The combined organic phases were dried over Na2SO4, filtered and concentrated. 
Purification of the crude reaction mixture by flash column chromatography afforded the 
corresponding N-Boc 9-bromo-10-substituted cytisine derivatives which were deprotected (see 
below) to provide 7, 9 and 11.  
(ii) General procedure B: N-Boc deprotection and conversion to HCl salt.  
The intermediate N-Boc C(10)-substituted (or C(9)-bromo-C(10)-disubstituted) cytisine 
derivative was dissolved in 0.5 M HCl in methanol (concentration of the substrate approx. 0.1 
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M) and the reaction mixture was stirred at room temperature for 72 h. The solvent was removed 
in vacuo, the residue was dissolved in the minimum amount of methanol, and acetone was added 
slowly to give approx. 1:10 v/v of methanol/acetone. After 2 h, the precipitated HCl salt was 
collected by filtration, washed with cold acetone and dried.  This provided final products of good 
purity and the salts were not purified further. 
 
3 Synthesis of C(10)-substituted cytisine derivatives.  
3.1  (+)-10-Aminocytisine.HCl 8.  
(i) N-Boc 10-aminocytisine. 
A resealable tube was charged with N-Boc 10-bromocytisine1 (1.85 g, 5 mmol), copper powder 
(32 mg, 10 mol%) and ammonium hydroxide (15 mL, conc. aq. sol.) was added. The tube was 
sealed the mixture was stirred at 100 °C (CAUTION) for 24 h, after which the solution was 
cooled to room temperature and extracted with DCM (5 x 50 mL). The combined extracts were 
dried over Na2SO4, filtered and concentrated in vacuo. Purification of the crude reaction mixture 
by flash column chromatography [DCM/MeOH/NH4OH: (89:10:1)] afforded the N-Boc 10-
aminocytisine (1.30 g, 85%) as an off-white solid.  During this procedure, some cleavage of the 
N-Boc residue (to give 10-aminocytisine 8 directly) was also observed by TLC. 
Rf: 0.28 [DCM/MeOH (10% MeOH)]; mp: >200 °C (toluene); FTIR (neat) 3414, 3302, 3211, 
2905, 1679, 1642, 1551 cm-1; 1H NMR (400 MHz, MeOD, δ) 5.83 (s, 1H, C9-H), 5.51 (s, 1H, 
C11-H), 4.29-4.02 (m, 3H, C6-Ha, C2-H, C4-H), 3.68 (dd, 1H, J = 6.5, 14.5 Hz, C6-Hb), 3.34-
2.93 (m, 3H, C1-H, C2-H, C4-H), 2.36 (s, 1H, C5-H), 1.98 (m, 2H, C13-H), 1.34-1.24 (m, 9H, 
Boc); 13C NMR (100 MHz, MeOD, δ) 165.2 (CO), 157.7 (CO Boc), 154.7 (C12), 149.0/148.8 
(C10, rotamers), 99.6/99.3 (C9, rotamers), 91.9 (C11), 80.1/79.6 (Boc, rotamers), 51.4/50.2/50.1 
(C2, C4, rotamers), 49.0 (C6), 34.9 (C1), 27.9/27.7 (C5, rotamers), 27.0 (Boc), 25.7 (C13); 
HRMS (ESI+) m/z [M+H]+ Calcd for C16H24N3O3 306.1812; Found 306.1809. 
(ii) 10-Aminocytisine.HCl 8. 
N-Boc 10-aminocytisine (1.0 mmol) was deprotected using the General Procedure B afforded 
(+)-10-aminocytisine.HCl 8 (273 mg, 98%) as an off-white solid.  
mp: >200 °C; [α]D25 = +77 [c 1.0, MeOH]; FTIR (neat) 2929, 2790, 1649, 1533 cm-1; 1H NMR 
(400 MHz, D2O, δ) 6.26 (s, 1H, C11-H), 4.09 (d, 1H, J = 15.0 Hz, C6-Ha), 3.95 (dd, 1H, J = 
6.5, 15.0 Hz, C6-Hb), 3.41-3.26 (m, 5H, C1-H, C2-H, C4-H), 2.68 (s, 1H, C5-H), 2.07-1.94 (m, 
2H, C13-H); Note: C9-H was not  observed in D2O (see comment relating to ligand 10 below). 
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13C NMR (100 MHz, D2O, δ) 161.4 (CO), 159.1 (C10), 148.1 (C12),104.5 (C9), 91.5 (C11), 
49.2 (C2 or C4), 48.8 (C6), 48.1 (C2 or C4), 31.2 (C1), 24.5 (C5), 22.5 (C13); HRMS (ESI+) 
m/z [M+H]+ Calcd for C11H16N3O 206.1288; Found 206.1292. 
3.2 (‒)-10-Fluorocytisine 2. 
To a solution of N-Boc 10-aminocytisine (305 mg, 1.0 mmol) in HF-pyridine complex (70%, 
2.0 mL) at -20 °C was slowly added tBuONO (0.18 mL, 1.5 mmol) over 1 min. The mixture 
was stirred at -20 °C for 30 min, warmed to room temperature and stirred for 2 h and finally 
heated at 60 °C overnight. The reaction mixture was cooled to 0 °C and taken to pH 10 with 
conc. aqueous NH3. The mixture was diluted with EtOAC (10 mL), filtered to remove insoluble 
material, the aqueous phase was extracted with EtOAc (4 x 10 mL) and the combined organic 
layers were concentrated in vacuo. The crude reaction mixture was partitioned between 3M HCl 
(5 mL) and DCM (5 mL). The aqueous layer was washed with DCM (2 x 5 mL), basified with 
concentrated NH4OH to pH 10 and extracted with DCM (5 x 5 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated in vacuo. Purification of the crude by 
flash column chromatography [DCM/MeOH/NH4OH (89:10:1)] gave (‒)-10-fluorocytisine 2 
(140 mg, 67%) as a pale-yellow solid. Note that N-Boc cleavage occurred under these reaction 
conditions and a pure sample of the free base was obtained by recrystallization in toluene.  
Rf: 0.25 [DCM/MeOH (20% MeOH)]; mp: 143-145 °C (toluene); [α]D25 = -92 [c 1.0, EtOH]; 
FTIR (neat) 3391, 3289, 1644, 1552 cm-1; 1H NMR (400 MHz, CDCl3, δ) 6.06 (dd, 1H, J = 
2.5, 11.0 Hz, C9-H), 5.87 (dd, 1H, J = 2.5, 7.0 Hz, C11-H), 4.04 (d, 1H, J = 15.5 Hz, C6-Ha), 
3.83 (dd, 1H, J = 6.5, 15.5 Hz, C6-Hb), 3.08-2.95 (m, 4H, C2-H, C4-H), 2.89-2.86 (m, 1H, C1-
H), 2.34-2.29 (m, 1H, C5-H), 1.93 (m, 2H, C13-H), 1.56 (br s, 1H, NH); 13C NMR (100 MHz, 
CDCl3, δ) 169.9 (d, J = 264 Hz, C10), 164.8 (d, J = 19 Hz, CO), 153.5 (d, J = 13.5 Hz, C12), 
99.6 (d, J = 16.5 Hz, C9), 96.5 (d, J = 26 Hz, C11), 53.7/52.9 (C2, C4), 49.8 (C6), 36.0 (d, J = 
2 Hz, C1), 27.5 (C5), 26.2 (C13); 19F NMR (376 MHz, CDCl3, δ) -99.6 (m); HRMS (ESI+) 
m/z [M+H]+ Calcd for C11H14FN2O 209.1090; Found 209.1095. Anal. Calcd for C11H13FN2O: 
C, 63.45; H, 6.29; N, 13.45. Found: C, 63.06; H, 6.33; N, 13.20. 
The corresponding HCl salt was prepared by dissolution of the free base in methanolic HCl and 
evaporation under vacuum for biological study. 
 
3.3  (‒)-10-Trifluoromethylcytisine.HCl 5.  
(i) N-Boc 10-iodocytisine 
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N-Boc 10-(Bpin)cytisine was prepared on a 5 mmol scale as previously described.1 
In a Schlenk flask, Cu(NO3)2·3H2O (2.42 g, 10.0 mmol), NH4I (1.45 g, 10.0 mmol) and 4 Ȧ 
molecular sieves (500 mg) were added to the crude borylation mixture (see above). The Schlenk 
flask was placed under nitrogen and backfilled with oxygen for three times. The reaction mixture 
was dissolved in DMF (25 mL) and heated at 80 °C for 24 h under an oxygen atmosphere 
(balloon). The solvent was removed in vacuo and the residue was dissolved in DCM. The 
mixture was poured over ammonia (30 mL, 15% aq. sol.), the layers separated, and the aqueous 
phase was extracted with DCM (3 x 25 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated. Purification of the crude reaction mixture by flash column 
chromatography [DCM/MeOH (2% MeOH)] gave N-Boc 10-iodocytsine (1.99 g, 95%) as a 
pale-yellow solid.  
Rf: 0.21 [DCM:MeOH (3% MeOH)] ; mp: 139 - 140 °C, needles (toluene); FTIR (neat) 2920, 
1679, 1632, 1523 cm-1; 1H NMR (500 MHz, CDCl3, δ, acquired at 52 °C to mitigate peak 
broadening) 6.90 (d, J = 2.0 Hz, 1H, C9-H), 6.37 (d, J = 2.0 Hz, 1H, C11-H), 4.39-4.04 (m, 3H, 
C2-H, C4-H, C6-H), 3.72 (dd, J = 16.0, 7.0 Hz, 1H, C6-H), 3.09-2.93 (m, 2H, C2-H, C4-H), 2.89 
(s, 1H, C1-H), 2.39 (s, 1H, C5-H), 1.99-1.87 (m, 2H, C13-H), 1.26 (s, 9H, Boc); 13C NMR (125 
MHz, CDCl3, δ, 52 °C) 161.6 (CO), 154.3 (Boc), 148.8 (C12), 126.3 (C9), 114.3 (C11), 108.2 
(C10), 80.1 (Boc), 50.4/49.3 (C2, C4), 48.8 (C6), 34.5 (C1), 28.1 (Boc), 27.5 (C5), 26.1 (C13) ; 
HRMS (ESI+) m/z [M+H]+ Calcd for C16H22IN2O3 417.0670; Found 417.0672; m/z [M+Na]+ 
Calcd for C16H21IN2NaO3 439.0489; Found 439.0491. 
(ii) N-Boc 10-trifluoromethylcytisine  
A Schlenk flask was charged with N-Boc 10-iodocytisine (2.08 g, 5.0 mmol), copper iodide 
(4.52 g, 23.7 mmol), anhydrous potassium fluoride (1.38 g, 23.7 mmol) and 
trimethyl(trifluoromethyl)silane (3.5 mL, 23.7 mmol) in DMF (24 mL). The reaction mixture 
was placed under nitrogen and stirred at 50 °C for 16 h. After this time, the solvent was removed 
in vacuo and the residue distributed between DCM (20 mL) and ammonia (20 mL, 15% aq. sol.). 
The aqueous phase was extracted with DCM (3 x 20 mL) and the combined organic phases were 
dried over Na2SO4, filtered and the solvent was removed in vacuo. Purification of the crude 
reaction mixture by flash column chromatography [EtOAc/n-Hexane (4:1)] yielded N-Boc-10-
trifluoromethylcytisine (1.52 g, 85%) as a colorless solid.  
mp: 150-151 °C (toluene); FTIR (neat) 2981, 1680, 1664, 1547 cm-1; 1H NMR (500 MHz, 
CDCl3, δ) 6.73 (s, 1H, C9-H), 6.22 (s, 1H, C11-H), 4.48-4.15 (m, 3H, C2-H, C4-H, C6-H), 3.85 
(dd, 1H, J = 16.0, 6.5 Hz, C6-H), 3.22-2.95 (m, 3H, C2-H, C4-H, C5-H), 2.49 (s, 1H, C1-H), 
 S21 
2.02 (m, 2H, C13-H), 1.43-1.15 (m, 9H, Boc); 13C NMR (125 MHz, CDCl3, δ) 162.2 (CO), 
154.5/154.0 (CO, rotamers), 151.4/151.0 (C12, rotamers), 141.0-139.5 (C10, poorly resolved 
due to amide resonance), 122.4 (q, J = 270 Hz, CF3), 114.2 (C9), 100.6/99.9 (C11, rotamers), 
80.6/80.0 (Boc, rotamers), 51.5/50.5/50.1/49.2 (C2, C4, rotamers), 49.3 (C6), 35.3 (C1), 27.9 
(Boc), 27.4 (C5), 25.9 (C13); 19F NMR (470 MHz, CDCl3, δ) -66.5 (d, J = 102 Hz); HRMS 
(ESI+) m/z [M+H]+ Calcd for C17H22F3N2O3 359.1577; Found 359.1584, m/z [M+Na]+ Calcd 
for C17H21F3N2NaO3 381.1396; Found: 381.1406; Anal. Calcd for C, 56.98; H, 5.91; N, 7.82. 
Found: C, 56.65; H, 5.55; N, 8.10. 
(iii) (-)-10-Trifluoromethylcytisine.HCl 5. 
N-Boc 10-trifluoromethylcytisine (100 mg, 0.28 mmol) was deprotected using the General 
Procedure B afforded (-)-10-trifluoromethylcytisine.HCl 5 (55 mg, 77%) as a colorless solid.  
mp: >200 °C; colorless powder; [α]D26 = -66 [c 0.5, MeOH]; FTIR (neat): 1658, 1551, 1278, 
1166, 857 cm-1; 1H NMR (500 MHz, D2O, δ) 6.82 (s, 1H, C9-H), 6.70 (s, 1H, C11-H), 4.11 (d, 
1H, J = 15.5 Hz, C6-H), 3.97 (d, 1H, J = 15.5, 6.5 Hz, C6-H), 3.53-3.30 (m, 5H, C2-H, C4-H, 
C1-H), 2.78 (s, 1H, C5-H), 2.05 (m, 2H, C13-H); 13C NMR (125 MHz, D2O, δ) 164.3 (CO), 
149.3 (C12), 141.5 (q, J = 34.0 Hz, C10), 122.2 (q, J = 273.0 Hz, CF3), 114.5 (C9), 104.4 (C11), 
49.2/48.9 (C2, C4), 48.2 (C6), 31.8 (C1), 24.7 (C5), 22.3 (C13); 19F NMR (376 MHz, D2O, δ) 
-66.2 (s); HRMS (ESI+) m/z [M+H]+ Calcd for C12H14F3N2O 259.1053; Found: 259.1060. 
 
3.4  (+)-10-(N-Methylamine)cytisine.HCl 10.  
(i) N-Boc 10-(N-methylamino)cytisine  
A resealable tube was charged with N-Boc 10-bromocytisine1 (369 mg, 1.0 mmol) and copper 
(7 mg, 10 mol%), and MeNH2 (2.0 mL, 40% aq. sol.) was added. The tube was sealed and 
mixture was stirred at 100 °C (CAUTION) for 24 h. The solution was cooled to room 
temperature and extracted with DCM (5 x 10 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated in vacuo. Purification of the crude reaction mixture by flash 
column chromatography (DCM/MeOH (94:6)] gave N-Boc 10-(N-methylamino)cytisine 
(274 mg, 86%) as an off-white solid.  
Rf: 0.58 [DCM/MeOH (10% MeOH)]; mp: 198-200 °C (toluene); FTIR (neat) 3266, 2928, 
1684, 1641, 1571 cm-1; 1H NMR (400 MHz, CDCl3, δ) 5.49 (s, 1H, C9-H), 5.37 (s, 1H, C11-
H), 4.53 (s, 1H, NH), 4.28-4.03 (m, 3H, C6-Ha, C2-H, C4-H), 3.72 (dd, 1H, J = 6.5, 15.0 Hz, 
C6-Hb), 3.02-2.70 (m, 6H, C1-H, C2-H, C4-H, NHMe), 2.31 (s, 1H, C5-H), 1.93-1.81 (m, 2H, 
C13-H), 1.32-1.22 (br s, 9H, Boc); 13C NMR (100 MHz, CDCl3, δ) 164.7 (CO), 156.0 (CO 
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Boc), 154.8/154.5 (C12, rotamers), 147.9/147.3 (C10, rotamers), 98.0/97.2 (C9, rotamers), 
90.4/90.1 (C11, rotamers), 80.2/79.6 (Boc, rotamers), 51.7/50.7/50.4/49.4 (C2, C4, rotamers), 
47.9 (C6), 34.8 (C1), 29.4 (NHMe), 28.1 (Boc), 27.6 (C5), 26.4 (C13); HRMS (ESI+) m/z 
[M+H]+ Calcd for C17H26N3O3 320.1969; Found 320.1974. 
 
(ii) (+)-10-(N-methylamino)cytisine.HCl 10. 
Following the general procedure B, N-Boc 10-(N-methylamino)cytisine (0.77 mmol) gave (+)-
10-(N-methylamino)cytisine.HCl 10 (190 mg, 85%) as a colorless solid.  
mp: >200 °C, colorless powder; [α]D25 = +66 [c 1.0, MeOH]; FTIR (neat): 3240, 2939, 2714, 
2583, 1644, 1557 cm-1; 1H NMR (400 MHz, D2O, δ) 6.25 (s, 1H, C11-H), 4.09 (d, 1H, J = 15.0 
Hz, C6-Ha,), 3.95 (dd, 1H, J = 6.5, 15.0 Hz, C6-Hb), 3.42-3.26 (m, 5H, C1-H, C2-H, C4-H), 
2.71 (m, 4H, C5-H, NHMe), 2.05-1.94 (m, 2H, C13-H) Note: as with 8, C9-H was not observed 
in D2O. In D6 DMSO we observed both C11-H and C9-H: 5.45 (d, 1H, J = 3.0 Hz) and 5.03 (d, 
1H, J = 3.0 Hz) which suggests that C9-H undergoes H/D exchange; 13C NMR (100 MHz, D2O, 
δ) 160.7 (CO), 158.7 (C10), 147.1 (C12),103.6 (C9), 88.4-87.9 (C11), 49.3 (C2 or C4), 48.7 
(C6), 48.1 (C2 or C4), 31.3 (C1), 28.5 (NHMe), 24.5 (C5), 22.6 (C13); HRMS (ESI+) m/z 
[M+H]+ Calcd for C12H18N3O 220.1444; Found 220.1441. 
 
4. Synthesis of 9-bromo-10-substituted cytisine derivatives.  
4.1  9-Bromo-10-ethylcytisine.HCl 7. 
(i) N-Boc 9-bromo-10-ethylcytisine . 
N-Boc 9-bromo-10-ethylcytisine was synthesised from N-Boc 10-ethylcytisine1 (341 mg, 1.07 
mmol) according to the General Procedure A. Purification of the crude reaction mixture by flash 
column chromatography [DCM:MeOH (1% MeOH)] afforded N-Boc 9-bromo-10-ethylcytisine 
(296 mg, 70%) as a colorless solid.  
FTIR (neat): 1676, 1638, 1590, 1425 cm-1; 1H NMR (400 MHz, CDCl3, δ) 6.00 (s, 1H, C11-
H), 4.43-4.03 (m, 3H, C2-H, C4-H, C6-H), 3.85 (dd, J = 15.5, 6.5 Hz, 1H, C6-H), 3.18-2.87 (m, 
3H, C1-H, C2-H, C4-H), 2.71-2.52 (m, 2H, CH2), 2.41 (m, 1H, C5-H), 2.01-1.89 (m, 2H, C13-
H), 1.44-1.04 (m, 12H, Boc, CH3); 13C NMR (100 MHz, CDCl3, δ)  159.3 (CO), 154.7/154.4 
(Boc, rotamers), 147.0/146.6 (C12, rotamers), 112.9 (C9), 106.6/105.8 (C11, rotamers), 
80.6/80.4 (Boc, rotamers), 51.6/ 50.6/50.4/49.3 (C2, C4, rotamers), 50.0 (C6), 34.6 (C1), 29.9 
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(CH2Me), 28.6 (Boc), 27.4 (C5), 26.1 (C13), 12.7 (CH2CH3), C10 was not observed; 
HRMS (ESI+) m/z [M+H]+  for C18H2679BrN2O3 397.1121; Found: 397.1121. 
(ii) 9-Bromo-10-ethylcytisine.HCl 7.  
N-Boc 9-bromo-10-ethylcytisine (296 mg, 0.75 mmol) was deprotected (General Procedure B) 
affording 9-bromo-10-ethylcytsine.HCl 7 (221 mg, quant) as a colorless solid.  
mp: > 200 °C; FTIR (neat: 2935, 1635, 1572, 1450 cm-1; 1H NMR (500 MHz, MeOD, δ) 6.52 
(s, 1H, C11-H), 4.44 (d, J = 15.5 Hz, 1H, C6-H), 4.01 (dd, J = 15.5, 6.5 Hz, 1H, C6-H), 3.62 (d, 
J = 13.5 Hz, 1H, C4-H), 3.52-3.44 (m, 4H, 2 x C2-H, C4-H, C1-H), 2.81 (s, 1H, C5-H), 2.71 
(m, 2H, CH2), 2.23 (d, J = 13.5 Hz, 1H, C13-H), 2.13 (d, J = 13.5 Hz, 1H, C13-H), 1.25 (t, J = 
7.5 Hz, 3H, CH3); 13C NMR (125 MHz, MeOD, δ) 159.9 (CO), 156.0 (C10), 144.9 (C12), 
112.9 (C9), 108.8 (C11), 49.6 (C6), 49.3/48.4 (C2, C4), 31.6 (C1), 29.4 (CH2Me), 25.4 (C5), 
22.9 (C13), 11.5 (CH2CH3); HRMS (ESI+) m/z [M+H]+ Calcd for C13H1879BrN2O 297.0597; 
Found: 297.0591. 
 
4.2 9-Bromo-10-aminocytisine.HCl 9. 
(i) N-Boc 9-bromo-10-aminocytisine.  
N-Boc 9-bromo-10-aminocytisine was synthesized from N-Boc 10-aminocytisine  (250 mg, 0.82 
mmol) according to the General Procedure A. Purification of the crude product by flash column 
chromatography [DCM:MeOH, (6% MeOH)] afforded N-Boc 9-bromo-10-aminocytisine (216 
mg, 68%) as a colorless solid.  
mp: > 200 °C (n-Hex:DCM); FTIR (neat): 3441, 1682, 1633, 1591, 1533, 1442 cm-1; 1H NMR 
(500 MHz, CDCl3, δ) 5.70 (s, 1H, C11-H), 4.61 (s, 2H, NH2), 4.43-4.05 (m, 3H, C2-H, C4-H, 
C6-H), 3.84 (dd, J = 13.5, 6.0 Hz, 1H, C6-H), 3.13-2.83 (m, 3H, C2-H, C4-H, C1-H), 2.38 (s, 
1H, C5-H), 1.95 (d, J = 13.0 Hz, 1H, C13-H), 1.92 (d, J = 13.0 Hz, 1H, C13-H), 1.44-1.21 (m, 
9H, Boc); 13C NMR (125 MHz, CDCl3, δ) 159.8 (CO), 154.8 (Boc), 151.5 (C10), 147.0 (C12), 
96.9 (C11), 91.4 (C9), 80.5 (Boc), 51.6/50.4 (C2, C4), 49.2 (C6), 34.7 (C1), 28.1 (Boc), 27.4 
(C5), 26.4 (C13); HRMS (ESI+) m/z [M+Na]+ Calcd for C16H2279BrN3NaO3 406.0737; Found: 
406.0741. 
(ii) 9-Bromo-10-aminocytisine.HCl 9.  
N-Boc 9-bromo-10-aminocytisine (260 mg, 0.68 mmol) was deprotected using the General 
Procedure B affording bromide 9 (189 mg, 98%) as a colorless solid. 
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mp: > 200 °C; FTIR (neat): 3319, 2934, 2756, 1641, 1454 cm-1; 1H NMR (500 MHz, MeOD, 
δ) 6.20 (s, 1H, C11-H), 4.41 (d, J = 15.5 Hz, 1H, C6-H), 3.95 (dd, J = 15.5, 6.5 Hz, 1H, C6-H), 
3.59 (d, J = 13.0 Hz, 1H, C2-H), 3.52-3.41 (m, 3H, C2-H, C4-H), 3.35 (s, 1H, C1), 2.75 (s, 1H, 
C5), 2.19 (d, J = 13.0 Hz, 1H, C13), 2.10 (d, J = 13.0 Hz, 1H, C13); 13C NMR (125 MHz, 
MeOD, δ)  159.9 (CO), 154.7 (C10), 144.9 (C12), 100.2 (C11), 89.3 (C9), 49.2/48.3 (C2, C4), 
48.9 (C6), 31.7 (C1), 25.4 (C5), 23.2 (C13); HRMS (ESI+) m/z [M+H]+ Calcd for 
C11H1579BrN3O 284.0393; Found: 284.0390. 
 
 
4.3 (+)-9-Bromo-10-(methylamino)cytisine.HCl 11. 
(i) N-Boc 9-bromo-10-(methylamino)cytisine  
N-Boc 9-bromo-10-(methylamino)cytisine was synthesised from N-Boc 
10-(methylamine)cytisine (96 mg, 0.30 mmol) according to the General Procedure A.  
Purification of the crude reaction mixture by flash column chromatography on silica gel 
[DCM/MeOH (2% MeOH)] gave N-Boc 9-bromo-10-(methylamino)cytisine (84 mg, 70%), 
which was used in the next step without further purification.  
FTIR (neat): 3290, 1633, 1493, 1206, 1100 cm-1; 1H NMR (500 MHz, CDCl3, δ) 5.68 (s, 1H, 
C11-H), 4.84 (s, 1H, NH), 4.36-4.05 (m, 3H, C2-H, C4-H, C6-H), 3.79 (dd, J = 6.5, 15.5 Hz, 
1H, C6-H), 3.13-2.85 (m, 6H, C2-H, C4-H, C1-H, NHMe), 2.33 (s, 1H, C5-H), 1.91 (m, 2H, 
C13-H), 1.36-1.13 (m, 9H, Boc); 13C NMR (125 MHz, CDCl3, δ) 159.2 (CO), 154.7/154.2 
(C12, rotamers), 152.4 (CO Boc), 148.0/147.7 (C10, rotamers), 93.0/92.5 (C11), 90.4 (C9), 
80.3/79.7 (Boc, rotamers), 51.6/50.6/50.2/49.3 (C2, C4 rotamers), 49.1 (C6), 35.0 (Me), 29.8 
(C1), 28.6 (Boc), 27.4 (C5), 26.3 (C13). 
(ii) 9-Bromo-10-(methylamino)cytisine.HCl 11. 
N-Boc 9-bromo-10-(methylamino)cytisine (67 mg, 0.21 mmol) was deprotected according to 
the General Procedure B affording 9-bromo-10-(methylamine)cytisine.HCl 11 (45 mg, 73%) as 
a colorless solid.  Small amounts (<10%) of 10-(methylamino)-11-bromo-cytisine were 
observable but this component could not be separated cleanly or fully characterized.  
[α]D23 = +38 [c 0.5, MeOH]; FTIR (neat): 3291, 2949, 2761, 2624, 1634, 1583 cm-1; 1H NMR 
(500 MHz, D2O, δ) 6.14 (s, 1H, C11-H), 4.13 (d, J = 15.5 Hz, 1H, C6-H), 3.88 (dd, J = 6.5, 
15.5 Hz, 1H, C6-H), 3.52-3.32 (m, 5H, C1-H, C2-H, C4-H), 2.84 (s, 3H, NHMe), 2.70 (s, 1H, 
C5-H), 2.04 (m, 2H, C13-H); 13C NMR (125 MHz, D2O, δ) 160.5 (CO), 154.3 (C12), 145.6 
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(C10), 97.0 (C9), 89.6 (C11), 49.3/48.5 (C2, C4), 48.9 (C6), 31.6 (C1), 28.9 (NHMe), 24.9 (C5), 
22.9 (C13); HRMS (ESI+) m/z [M+H]+ Calcd for C12H1779BrN3O 298.0549; Found: 298.0548.  
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5. 1H and 13C NMR spectra.  
(‒)-10-Fluorocytisine 2: 
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(‒)-10-Trifluoromethylcytisine.HCl 5:  
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(+)-10-Aminocytisine.HCl 8: 
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(+)-10-(N-Methylamine)cytisine.HCl 10: 
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9-Bromo-10-ethylcytisine.HCl 7: 
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9-Bromo-10-aminocytisine.HCl 9: 
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9-Bromo-10-(methylamino)cytisine.HCl 11: 
 
 
 
